Canada Avandia Heart Injury Class Action Settlement

The deadline to submit claims in the Canada Avandia Heart Injury Class Action Settlement is Wednesday! If you’re eligible to claim compensation in this class action settlement you must submit a claim and the necessary medical records by July 15, 2020 to benefit from this settlement.

GlaxoSmithKline has agreed to pay up to $6.75 million (CAD) to settle a Canadian class action lawsuit that claims the diabetes medication Avandia may have life-threatening side effects including heart attacks and heart failure.

Canadian residents who took Avandia for a minimum of 30 days before December 2010 and then suffered a heart attack, heart failure, coronary artery bypass graft (CABG surgery), or percutaneous coronary intervention with stent placement, are eligible for payments of up to $18,333 from this settlement.

These injuries must have occurred within one year of taking Avandia, and if the Class Member is now deceased an estate representative may file a claim on their behalf.

The Avandia class action lawsuit was filed by plaintiffs Albert Carl Sweetland and Barbara Fontaine who allege the type-2 diabetes medication was linked to serious cardiovascular injuries.

The plaintiffs sought compensation on behalf of all Canadians who were prescribed and took Avandia (rosiglitazone maleate) and later experienced heart damage.

Settlement compensation varies depending on the severity of the injury but ranges between $3,333 and $18,333. The defendant has agreed to a maximum payout amount of $6.75 million so if the number of valid claims exceeds this amount Class Members will receive a lower pro rata payment.

Class Members must submit a claim and provide all the necessary medical records by July 15, 2020 to benefit from this settlement.

The Avandia class action settlement was granted final approval on June 13, 2019. The opt out deadline has passed.

Who’s Eligible

The Avandia class action settlement benefits all Canadian residents who were prescribed and took Avandia for a minimum of 30 consecutive days before December 2010 and then suffered a heart attack, heart failure, coronary artery bypass graft (CABG surgery), and percutaneous coronary intervention with stent placement. One of these injuries much have occurred within one year of taking Avandia.

If a Class Member is now deceased, an estate representative may file a claim on their behalf.

Potential Award

$3,333 to $18,333.

$3.6 million will be set aside to pay up to 200 claimants who meet the requirements for a myocardial infarction (MI), coronary artery bypass grafting (CABG), and cardiac stenting procedures (Stenting) claim. If more than 200 Class Members file valid claims the defendant has agreed to pay an additional $18,333 per Class Member up to 300 claimants.

$200,000 will be used to pay up to 60 Class Members who file a congestive heart failure claim. If more than 60 Class Members file valid claims, the defendants will pay $3,333 for up to 300 claimants.

The defendants have agreed to pay no more than $6.75 million, if the number of claims exceed this cap, then payments will be modified on a pro rata basis.

Proof of Purchase

Class Members are required to provide proof in the form of medical records, physician records along with a letter from treating physician, and/or pharmacy records that show the following:

“a) contemporaneous medical records demonstrating one or more of the following cardiac events:

i. a final diagnosis of a Myocardial Infarction (‘MI’) (which includes a final diagnosis in medical records generated in the course of medical care that interpret clinical signs and/or diagnostic tests as establishing the occurrence of an MI at or about such time or, alternatively for purposes of this criterion, death from a cardiac event in the absence of any other cause of death);

ii. underwent a Coronary Artery Bypass Graft;

iii. underwent percutaneous coronary intervention with stent placement;

iv. a final diagnosis of initial onset or exacerbation of Congestive Heart Failure (which includes a final diagnosis in medical records generated in the course of medical care that interprets clinical signs and/or diagnostic tests as establishing the initial onset or exacerbation of CHF at or about such time) and

b) contemporaneous medical and/or pharmacy records demonstrating Avandia consumption for at least 30 days at the time of, or within one year prior to, such cardiac event; and

c) contemporaneous medical and/or pharmacy records demonstrating that the 30 days of Avandia use occurred prior to December 2010, or that an uninterrupted period of such use began prior to December 2010.”

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

7/15/2020

Case Name

Albert Carl Sweetland, et al. v. GlaxoSmithKline Inc., et al., Case No. 315567, in the Supreme Court of Nova Scotia, Canada

Final Hearing

1/29/2019

Settlement Website

AvandiaClassAction.com

Claims Administrator

Avandia Class Action
c/o RicePoint Administration Inc.
PO Box 4454, Toronto Station A
25 The Esplanade
Toronto, ON M5W 4B1

866-458-2144
Info@AvandiaClassAction.com

Class Counsel

SISKINDS LLP

WAGNERS

Defense Counsel

GOWLING WLG (CANADA) LLP

Read More Lawsuit & Settlement News:

Canada Festival Metro Metro Class Action Settlement

Canada Roundup Class Action Seeks $500M In Damages

Canada Subaru, Toyota, Mazda Airbags Class Action Settlement

Symptoms of Cerebellar Atrophy May Be Caused by Dilantin